...
首页> 外文期刊>Drug Design, Development and Therapy >Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
【24h】

Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli

机译:大肠杆菌中抗血管生成和抗肿瘤小肽的创新生产方法

获取原文
           

摘要

Background: Developing innovative drugs with potent efficacy, specificity, and high safety remains an ongoing task in antitumor therapy development. In the last few years, peptide drugs have become attractive agents in cancer therapy. HM-3, mainly with antiangiogenic effect, and AP25, with an additional antiproliferative effect, are two peptides designed in our laboratory targeting αvβ3 and α5β1 integrins, respectively. The low molecular weight of the two peptides renders their recombinant expression very difficult, and the complicated structure of AP25 makes its chemical synthesis restricted, which presents a big challenge for its development. Methods: Bifunctional peptides designed by the ligation of HM-3 and AP25, using linkers with different flexibility, were prepared using recombinant DNA technology in Escherichia coli . The fusion peptides were expressed in a modified auto-induction medium based on a mixture of glucose, glycerol, and lactose as carbon substrates and NH4+ as nitrogen source without any amino acid or other elements. Subsequently, the antiangiogenic, antiproliferative, and cell adhesion assays were conducted to evaluate the bioactivity of the two fusion peptides. Results: The peptides were successfully expressed in a soluble form without any induction, which allows the culture to reach higher cell density before protein expression occurs. Human umbilical vein endothelial cell migration assay and chick embryo chorioallantoic membrane assay showed, at low doses, a significantly increased antiangiogenic effect (>75%) of the purified products compared with the single molecules. Meanwhile, MTT assay confirmed their enhanced antitumor activity against gastric cancer cell line MGC-803; however, no significant effect was observed on hepatoma HepG2 cells and no cytotoxicity on normal human lens epithelial cell SRA01/04 and human epithelial esophageal cells. Conclusion: Bifunctional molecules with antiangiogenic and antiproliferative effects were obtained by using this technique, which presents an alternative for small peptide production, instead of the conventional chemical method. The increased molecular weight facilitates the peptide expression with a simultaneous improvement in their stability and biological activity.
机译:背景:开发具有有效功效,特异性和高安全性的创新药物仍然是抗肿瘤治疗开发中的一项持续任务。在最近几年中,肽药物已成为癌症治疗中的诱人药物。 HM-3主要具有抗血管生成作用,AP25具有附加的抗增殖作用,是我们实验室针对α v β 3 和α 5设计的两种肽β 1 整合素。两种肽的低分子量使得它们的重组表达非常困难,并且AP25的复杂结构使其化学合成受到限制,这为其开发提出了巨大挑战。方法:利用重组DNA技术,在大肠杆菌中制备具有不同柔韧性的接头,通过HM-3和AP25的连接设计的双功能肽。在以葡萄糖,甘油和乳糖为碳底物,以NH 4 + 为氮源且不含任何氨基的混合物的改良自动诱导培养基中表达融合肽酸或其他元素。随后,进行了抗血管生成,抗增殖和细胞粘附试验,以评估两种融合肽的生物活性。结果:肽成功地以可溶形式表达而没有任何诱导,这使得培养物可以在蛋白质表达发生之前达到更高的细胞密度。人脐静脉内皮细胞迁移测定和鸡胚绒膜尿囊膜测定显示,在低剂量下,与单分子相比,纯化产物的抗血管生成作用显着提高(> 75%)。同时,MTT测定证实了它们对胃癌细胞MGC-803的增强的抗肿瘤活性。然而,未观察到对肝癌HepG2细胞的显着影响,对正常人晶状体上皮细胞SRA01 / 04和人上皮食管细胞没有细胞毒性。结论:利用该技术获得了具有抗血管生成和抗增殖作用的双功能分子,为小肽生产提供了一种替代方法,代替了常规化学方法。增加的分子量促进了肽表达,同时提高了它们的稳定性和生物学活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号